Luca Baldo

Stories

Beacon's gene therapy for inherited blindness hits primary goal in pivotal trial

As of September 2026: Leading Beacon toward a rolling BLA submission

X-linked retinitis pigmentosa gradually destroys the retinas of young men, and no treatment has ever slowed it. Beacon Therapeutics' gene therapy laru-zova is now the first to clear a pivotal trial, and the company says it will file for US approval later this year.

Updated Sep 21